NeuroOne to Participate in Alliance Global Partners (A.G.P.) Virtual MedTech Summer Conference on July 29, 2021
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Alliance Global Partners Virtual MedTech Summer Conference on July 29, 2021. The event will feature one-on-one virtual meetings between investors and management. NeuroOne focuses on developing advanced EEG recording and ablation solutions for neurological disorders like epilepsy and Parkinson's disease. The company recently achieved a key milestone in its distribution agreement with Zimmer Biomet, further enhancing its market position.
- None.
- None.
EDEN PRAIRIE, Minn., July 28, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the Company will participate in Alliance Global Partners (A.G.P.) Virtual MedTech Summer Conference on July 29, 2021.
The event will consist of one-on-one virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with management should contact their A.G.P. representative or James@HaydenIR.com .
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.
The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne's Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-participate-in-alliance-global-partners-agp-virtual-medtech-summer-conference-on-july-29-2021-301342767.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
When is NeuroOne participating in the A.G.P. Virtual MedTech Summer Conference?
What is NeuroOne's focus in the medical technology field?
What milestone did NeuroOne achieve with Zimmer Biomet?
What technology did NeuroOne receive FDA clearance for?
Who are NeuroOne's key partners in developing cortical technology?
